1st Quarter - Report

BRIDGEBIO PHARMA, INC. for BRIDGEBIO PHARMA, INC.

Firm
Client
Income
—
Expenses
$320,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Give Kids a Chance Act of 2025 - H.R. 1262; S. 932 Orphan drug policies Scientific EXPERT Act of 2024 - H.R.1532; S. 822 Cameron's Law - H.R. 1414 FY25 Full Year Continuing Appropriations and Extensions Act - H.R. 1968

LobbyistCovered position, as disclosed
MICHAEL CALVO —
AMANDA MALAKOFF —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 932 (119th), H.R. 1968 (119th), S. 822 (119th), H.R. 1262 (119th), H.R. 1532 (119th), H.R. 1414 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.